First Sofosbuvir WHO Prequalification To Widen Access But How Far?
Executive Summary
WHO’s prequalification of the first sofosbuvir from Gilead licensee Mylan is expected to expand access to the HCV treatment, but much will depend on donor funding priorities, say experts. Gilead hopes direct negotiations with payers in certain territories can move the access needle further.